Sponsored Content
Intercell
Valneva Completes EUR 45 Million Capital Increase
The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.
February 4, 2015
Intercell Announces Pediatric Approval of its Japanese Encephalitis
Vaccine in the U.S.
Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.
May 21, 2013
Intercell AG / Merger between Intercell and Vivalis planned to
complete on May 28, 2013 - Relevant documents filed with the Commercial Court of
Lyon
Intercell AG / Merger between Intercell and Vivalis planned to complete on May 28, 2013 - Relevant documents filed with the Commercial Court of Lyon
May 14, 2013
Intercell AG / Vivalis SA shareholders approved the proposed merger
of equals to create Valneva SE
Intercell AG / Vivalis SA shareholders approved the proposed merger of equals to create Valneva SE
March 7, 2013
Intercell AG announces Q4 and preliminary full year 2012 financial
results and business update
Intercell AG announces Q4 and preliminary full year 2012 financial results and business update
March 5, 2013
Intercell AG / Intercell announces pediatric approval of its Japanese
Encephalitis vaccine in Europe
Intercell AG / Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe
February 12, 2013
Intercell AG / Intercell and Vivalis provide update on the progress
towards intended merger
Intercell AG / Intercell and Vivalis provide update on the progress towards intended merger
January 28, 2013
Intercell receives CHMP positive opinion for the pediatric indication
of its Japanese Encephalitis vaccine in Europe
Intercell receives CHMP positive opinion for the pediatric indication of its Japanese Encephalitis vaccine in Europe
December 19, 2012
Intercell AG announces Q3 2012 financial results and provides
operational update
Intercell AG announces Q3 2012 financial results and provides operational update
November 7, 2012
Intercell AG provides update on IXIARO®/JESPECT® sales growth and
expected full year financial performance
Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance
October 16, 2012
Vienna Stock Exchange: Winners and Losers (2012-06-02)
Daily News Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Analyzes and Comments.
June 2, 2012
Intercell Completes Equity Private Placement
The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.
May 15, 2012
Intercell Remains in the Loss Area
The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.
May 8, 2012
Vienna Stock Exchange: Winners and Losers (2012-05-07)
Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
May 7, 2012 · Updated: May 7, 2012; 18:33
Vienna Stock Exchange: Winners and Losers (2012-04-27)
Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
April 27, 2012
Vienna Stock Exchange: Winners and Losers (2012-03-07)
Daily News Flash from Vienna Stock Exchange. Upgrades and Downgrades, Winners and Losers.
March 7, 2012 · Updated: March 7, 2012; 19:41
Intercell Does Not Leave the Loss zone
The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.
March 6, 2012
Vienna Stock Exchange: Winners and Losers (2012-02-25)
Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
February 25, 2012
Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
February 6, 2012
Vienna Stock Exchange: Winners and Losers (2012-01-18)
Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners & Losers.
January 18, 2012 · Updated: January 18, 2012; 17:58
Vienna Stock Exchange: Winners and Losers (2012-01-16)
Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
January 16, 2012
New Chairman for Intercell’s Supervisory Board
Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.
December 30, 2011
Vienna Stock Exchange: Winners and Losers (2011-12-10)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
December 10, 2011
Vienna Stock Exchange: Winners and Losers (2011-12-09)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
December 9, 2011 · Updated: December 9, 2011; 18:00
Vienna Stock Exchange: Winners and Losers (2011-12-08)
Daily News-Flash from the Vienna Stock Exchange. Upgrades & Downgrades, Winners & Losers.
December 8, 2011
Vienna Stock Exchange: Winners and Losers (2011-11-16)
Daily News-Flash from the Vienna Stock Exchange. Upgrades & Downgrades, Winners & Losers.
November 16, 2011
Intercell Receives Approval for Vaccine in India
The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.
November 10, 2011
Intercell Still Reports Losses
The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.
November 8, 2011
Vienna Stock Exchange: Winners and Losers (2011-11-02)
Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
November 2, 2011
R&D Expenses on the Rise
The largest Austrian Enterprises increased their budgets for research & development by 9.6% on average. This is slightly beyond the global average (9.3%).
October 24, 2011
Intercell Continues Development of Vaccines
The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.
October 24, 2011
29 Austrian Companies Ranked in "EU Industrial R&D Investment Scoreboard"
Benteler International, Voestalpine, Borealis, Intercell, Zumtobel are the first five Austrian firms in the “EU Industrial R&D Investment Scoreboard”. The ranking was prepared by the European Commission.
October 19, 2011
Intercell: EU Invests € 30m in Research Program
The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.
September 29, 2011
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Intercell Successfully Completes Vaccine Study in India
The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.
September 16, 2011
Vienna Stock Exchange: Winners and Losers (2011-09-07)
Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.
September 7, 2011
Vienna Stock Exchange: Winners and Losers (2011-08-18)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
August 18, 2011
Intercell: Restructuring Is Progressing
Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.
August 16, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-30)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 30, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-24)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 24, 2011
Intercell: “We Will Stabilize Our Share Price”
The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.
June 21, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-15)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 15, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-14)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 14, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-10)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 10, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-09)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 9, 2011
Vienna Stock Exchange: Winners and Losers (2011-06-08)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
June 8, 2011
Intercell to Cut Jobs and Research Budget
The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.
June 8, 2011
Vienna Stock Exchange: Winners and Losers (2011-05-23)
Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.
May 23, 2011
